国邦医药: 国邦医药集团股份有限公司简式权益变动报告书（仕琦汇）

Core Viewpoint - The report outlines a shareholding change in Guobang Pharmaceutical Group Co., Ltd., where the shareholder, Weifang Shiqihui Equity Investment Partnership (Limited Partnership), is transferring 4.91% of its shares to Zhejiang State-owned Capital Operation Co., Ltd. through a private agreement, resulting in a decrease in its shareholding from 8.95% to 4.04% [1][5][6]. Group 1: Shareholding Change Details - The share transfer involves 27,445,600 shares, which represents a significant reduction in the shareholder's stake [6][7]. - The agreed transfer price is 20.66 RMB per share, totaling approximately 791.41 million RMB for the entire transaction, with the transferring party receiving about 567.03 million RMB for its portion [6][7]. - The transfer is subject to compliance confirmation from the Shanghai Stock Exchange and subsequent registration with the China Securities Depository and Clearing Corporation [3][8]. Group 2: Purpose and Future Plans - The purpose of this share transfer is to introduce strategic investors who recognize the company's value and future development potential, while also meeting the needs of some shareholders to reduce their holdings [5]. - There are currently no plans for the shareholder to increase or decrease its stake in the next 12 months, aside from this transfer [5][6]. Group 3: Shareholder Information - The transferring entity, Weifang Shiqihui, is a limited partnership established on July 10, 2019, with a registered capital of 329.99 million RMB [4]. - The main responsible person of the transferring entity is Liao Shixue, who resides in Hangzhou, China [4]. Group 4: Compliance and Legal Framework - The report is prepared in accordance with the Securities Law of the People's Republic of China and relevant regulations, ensuring that all necessary authorizations and approvals have been obtained [1][2]. - The report confirms that there are no restrictions on the shares being transferred, such as pledges or freezes [8].